Compare TOMZ & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOMZ | CTXR |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 16.8M |
| IPO Year | 2009 | 2010 |
| Metric | TOMZ | CTXR |
|---|---|---|
| Price | $0.59 | $0.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.50 | ★ $6.00 |
| AVG Volume (30 Days) | 217.6K | ★ 611.9K |
| Earning Date | 05-07-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,738,842.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $68.67 | $147.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.23 | N/A |
| 52 Week Low | $0.54 | $0.63 |
| 52 Week High | $1.20 | $2.38 |
| Indicator | TOMZ | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 38.60 | 46.81 |
| Support Level | $0.54 | $0.70 |
| Resistance Level | $0.81 | $0.98 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 42.03 | 32.10 |
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage (7.8%) hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. Its product portfolio includes The SteraPak, The Surface Unit, The Transport, The NV+, The Environment System, SteraMist Integrated System, BIT Solution, and Custom Engineered System.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.